Form 4: Lyell CEO Lynn Seely Acquires Shares, Options

Lyell Immunopharma's President and CEO, Lynn Seely, reported the acquisition of 20,000 common shares from RSU vesting and 155,000 stock options, alongside a sale of 438 shares for tax purposes.

Summary

• Lynn Seely, President and CEO of Lyell Immunopharma, Inc. (LYEL), acquired 20,000 shares of common stock on February 9, 2026, through the vesting of performance-based restricted stock units.
• The compensation committee certified the achievement of performance criteria for these RSUs.
• On February 10, 2026, 438 shares were automatically sold at $23.12 per share to cover tax withholding obligations related to the vested RSUs.
• Seely also acquired an option to buy 155,000 shares of common stock on February 10, 2026, with an exercise price of $23.71.
• The option vests 12.5% six months after February 9, 2026, and then 1/48th monthly, subject to continued service, expiring on February 9, 2036.
• Following these transactions, Seely beneficially owns 81,721 shares of common stock and options for 155,000 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting the achievement of performance milestones and continued alignment of executive incentives with long-term company performance through new equity grants.

Positives

• CEO Lynn Seely acquired 20,000 shares of common stock through the vesting of performance-based restricted stock units, indicating the achievement of company performance criteria.
• The grant of 155,000 stock options aligns management's incentives with long-term shareholder value creation.

Negatives

• A sale of 438 shares occurred to cover tax withholding obligations, which is a standard practice but represents a minor reduction in direct shareholding.

Future Outlook

The vesting schedule for the newly granted stock options extends through February 9, 2036, indicating a long-term incentive structure tied to the reporting person's continued service to the Issuer.

Management Comments

• Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date.
• Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
• Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one forty-eighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity grants like RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries. These grants are designed to align executive interests with long-term shareholder value, especially in companies like Lyell Immunopharma, which often have long development cycles for their therapeutic candidates. The vesting of performance-based RSUs suggests the company met specific operational or financial milestones.

Comparison to Industry Standards

• The grant of performance-based restricted stock units and stock options to a CEO is a common compensation structure in the biotech sector, comparable to practices at companies like Gilead Sciences or Amgen, where executive incentives are heavily weighted towards equity to encourage long-term value creation.
• The specific vesting schedule for options (12.5% after 6 months, then monthly over several years) is typical for retaining key executives and motivating sustained performance, similar to long-term incentive plans seen at peer companies developing novel immunotherapies.
• The automatic sale of shares to cover tax withholding is a standard, non-discretionary event for RSU vesting across all industries, not indicative of a specific company or industry trend.

Stakeholder Impact

• Shareholders: The vesting of performance-based RSUs suggests the company met certain internal targets, which could be viewed positively. The grant of new options aligns executive interests with long-term shareholder value.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• Lynn Seely will continue to provide service to Lyell Immunopharma to meet the vesting conditions for the remaining stock options.
• Future vesting events for the 155,000 stock options will occur monthly after the initial 12.5% vesting six months post-February 9, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, including the vesting of performance-based restricted stock units and the grant of new stock options, along with a standard tax-related share sale. While the achievement of performance criteria is positive, these transactions are largely expected and do not introduce new fundamental information that would significantly alter the investment thesis for Lyell Immunopharma. Therefore, a "hold" recommendation is appropriate as the filing confirms ongoing executive alignment and performance but does not present a catalyst for a strong buy or sell decision.

Keywords

Lyell Immunopharma, LYEL, Lynn Seely, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Executive Compensation, Biotechnology, Immunotherapy